我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

血管平滑肌细胞表型转化与血管钙化

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第5期
页码:
617-620,628
栏目:
综述
出版日期:
2015-05-05

文章信息/Info

Title:
Vascular smooth muscle cell phenotypic switching in vascular calcification
作者:
林 芳刘 越傅 羽尹新华
(哈尔滨医科大学附属第一医院心内科,黑龙江 哈尔滨 150001)
Author(s):
LIN Fang LIU Yue FU Yu YIN Xin-hua
(Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China)
关键词:
血管平滑肌表型转化标志物血管钙化
Keywords:
vascular smooth muscle cell phenotypic switching markers vascular calcification
分类号:
R543
DOI:
-
文献标识码:
A
摘要:
血管钙化是一种由细胞所介导、主动的生物矿化过程,可增加心血管疾病的患病率和死亡率,并严重危害人类的健康和生活。越来越多的研究证实血管平滑肌细胞(Vascular smooth muscle cell,VSMC)及表型转化(phenotypic switching)在血管钙化的发生发展中具有重要作用。本文将阐述VSMC的表型转化,向骨/软骨化表型转化不同时期的标志蛋白分子,并探讨其表型转化的调控因素,进而深入认识血管钙化的发病过程。
Abstract:
Vascular calcification (VC), an active, cell-mediated process of biomineralization, often poses a threat to human health and leads to cardiovascular morbidity and mortality. An increasing body of evidence confirms that vascular smooth muscle cells (VSMCs) and their phenotypic transformation play significant roles in VC. To add to our knowledge of VC, this review will focus on markers of osteochondrocyte-like VSMCs and explore factors regulating the transdifferentiation of VSMCs.

参考文献/References

[1]Shi N,Chen SY.Mechanisms simultaneously regulate smooth muscle proliferation and differentiation[J].J Biomed Res, 2014,28(1):40-46.
[2]Wang L,Zhang J,Fu W,et al.Association of smooth muscle cell phenotypes with extracellular matrix disorders in thoracic aortic dissection[J].J Vasc Surg,2012,56(6):1698-1709.
[3]Speer MY,Li X,Hiremath PG,et al.Runx2/Cbfa1,but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis[J].J Cell Biochem,2010,110(4):935-947.
[4]Ciceri P,Volpi E,Brenna I,et al.Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation[J].Nephrol Dial Transplant,2012,27(1):122-127.
[5]Tada Y,Yano S,Yamaguchi T,et al.Advanced glycation end products-induced vascular calcification is mediated by oxidative stress:functional roles of NAD(P) H-oxidase[J].Horm Metab Res,2013,45(04):267-272.
[6]Confavreux CB,Szulc P,Casey R,et al.Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort[J].J Clin Endocrinol Metab,2013,98(3):1084-1092.
[7]Gon?alves FB,Vo?te MT,Hoeks SE,et al.Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis[J].Heart,2012,98(13): 988-994
[8]Lei Y,Sinha A,Nosoudi N,et al.Hydroxyapatite and calcified elastin induce osteoblast-like differentiation in rat aortic smooth muscle cells[J].Exp Cell Res,2014,323(1):198-208.
[9]Shanahan CM,Crouthamel MH,Kapustin A,et al.Arterial calcification in chronic kidney disease:key roles for calcium and phosphate[J].Circ Res,2011,109(6):697-711.
[10]Han MS,Che X,Cho G,et al.Functional Cooperation between Vitamin D Receptor and Runx2 in Vitamin D-Induced Vascular Calcification[J].PLoS One,2013,8(12):e83584.
[11]Lee SY,Kim HY,Gu SW,et al.25-hydroxyvitamin D levels and vascular calcification in predialysis and dialysis patients with chronic kidney disease[J].Kidney Blood Press Res,2012,35(5):349-354.
[12]Suga T,Iso T,Shimizu T,et al.Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells[J].J Atheroscler Thromb,2010,18(8):670-683.
[13]Brodeur MR,Bouvet C,Bouchard S,et al.Reduction of advanced-glycation end products levels and inhibition of rage signaling decreases rat vascular calcification induced by diabetes[J].PloS One,2014,9(1):e85922.
[14]Dautova Y,Kozlova D,Skepper JN,et al.Fetuin-A and Albumin Alter Cytotoxic Effects of Calcium Phosphate Nanoparticles on Human Vascular Smooth Muscle Cells[J].PloS One,2014,9(5):e97565.
[15]Scialla JJ,Kao WH,Crainiceanu C,et al.Biomarkers of Vascular Calcification and Mortality in Patients with ESRD[J].Clin J Am Soc Nephrol,2014,9(4):745-755.
[16]Airola MV,Hannun YA.Sphingolipid metabolism and neutral sphingomyelinases[M]//Sphingolipids:Basic Science and Drug Development.2013,57-76.
[17]Khavandgar Z,Poirier C,Clarke CJ,et al.A cell-autonomous requirement for neutral sphingomyelinase 2 in bone mineralization[J].J Cell Biol,2011,194(2):277-289.
[18]Kakoi H,Maeda S,Shinohara N,et al.Bone morphogenic protein(BMP)signaling up-regulates neutral sphingomyelinase 2 to suppress chondrocyte maturation via the Akt protein signaling pathway as a negative feedback mechanism[J].J Biol Chem,2014,289(12):8135-8150.
[19]Morris T,Ohanian V,Canfield A,et al.The Role of Bioactive Sphingolipids in Vascular Calcification[J].Heart,2014,100(3):A98-A98.
[20]Duran-Prado M,Morell M,Delgado-Maroto V,et al.Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation[J].Circ Res,2013,112(11):1444-1455.
[21]Chen NX,O’Neill KD,Chen X,et al.Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease[J].Am J Nephrol,2011,34(3): 211-219.
[22]Shan A,Zhou C,He Y,et al.Expression of both matrix metalloproteinase-2 and its tissue inhibitor-2 in tunica media of radial artery in uremic patients[J].Ren Fail,2013,35(1):37-42.

备注/Memo

备注/Memo:
收稿日期:2014-10-15.
基金项目:国家级大学生创新创业训练计划项目资助(201310226010);哈尔滨市科技创新人才研究专项资金项目资助(2012RFXXS008);国家自然科学基金项目资助(81200235、81200143)
通讯作者:尹新华,主任医师,主要从事心血管疾病基础研究 Email:liuyue198002 @163.com
作者简介:林芳,博士生 Email:linfang2008lf @126.com
更新日期/Last Update: 2015-04-28